FRESHFIELDS BRUCKHAUS DERINGER

Comment: This recommended pharma practice mainly has people talking in the market due to its frequent involvement in complex transactions and licensing deals. Recently, for instance, licensing expert Dieselhorst was involved in what can only be described as the deal of the German biotech industry when he represented the Ganymed shareholders in the sale to Astellas. In terms of regulatory advice, which comes in the form of public law expert Kaufmann, Freshfields continues to focus on complex cross-border projects. As also seen with competitors, advice at the interface with compliance has proven to be an important driving force here. Just like Clifford Chance, Freshfields boosted its team by appointing an internal partner: Dr. Michael Ramb focuses not only on the healthcare industry but also on related product areas such as food and chemistry.
Strengths: Transactions ( ?M&A), licensing deals, ?patent proceedings.
Recommended: Dr. Frank-Erich Hufnagel (“excellent analyst and litigator”, competitor; patents), Prof. Dr. Marcel Kaufmann (regulatory aspects), Dr. Jochen Dieselhorst (licenses/IT/IP).
Practice: Primary focus on transactions, licensing contracts, patent proceedings with pharma aspects, product liability and regulatory issues. Also approval, strategic advice on healthcare policy and ?compliance. Good ties to the ?antitrust lawyers. Clients: mainly pharma research companies and biotech companies. (Core team: 4 partners, 12 associates)
Clients: ?? Ganymed shareholders on sale to Astellas; EQT on sale of BSN Medical; Boehringer Ingelheim on business swap with Sanofi; Genomic Health on regulatory and reimbursement matters concerning gene expression test; BioNTech in strategic collaboration with Roche subsidiary Genentech.
  • Teilen